Quince Therapeutics Reports Positive Safety Review for Phase 3 NEAT Trial in Ataxia-Telangiectasia

Reuters11-11

Quince <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Safety Review for Phase 3 NEAT Trial in Ataxia-Telangiectasia

Quince Therapeutics Inc. announced a positive outcome from a pre-planned safety analysis conducted by an independent data and safety monitoring board (iDSMB) for its ongoing pivotal Phase 3 NEAT clinical trial. The study is evaluating encapsulated dexamethasone sodium phosphate (eDSP) in patients with Ataxia-Telangiectasia (A-T). The iDSMB identified no safety concerns and recommended that the trial continue without modifications. The Phase 3 NEAT study is a randomized, double-blind, placebo-controlled trial assessing the neurological effects of eDSP. Topline results from the study are expected to be reported in the first quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251021956399) on November 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582800808?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 05:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582800808","market":"nz","top_or_hot":-1,"title":"Quince Therapeutics Reports Positive Safety Review for Phase 3 NEAT Trial in Ataxia-Telangiectasia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Quince <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Safety Review for Phase 3 NEAT Trial in Ataxia-Telangiectasia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Quince Therapeutics Inc. announced a positive outcome from a pre-planned safety analysis conducted by an independent data and safety monitoring board (iDSMB) for its ongoing pivotal Phase 3 NEAT clinical trial. The study is evaluating encapsulated dexamethasone sodium phosphate (eDSP) in patients with Ataxia-Telangiectasia (A-T). The iDSMB identified no safety concerns and recommended that the trial continue without modifications. The Phase 3 NEAT study is a randomized, double-blind, placebo-controlled trial assessing the neurological effects of eDSP. Topline results from the study are expected to be reported in the first quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251021956399) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quince Therapeutics Reports Positive Safety Review for Phase 3 NEAT Trial in Ataxia-Telangiectasia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuince Therapeutics Reports Positive Safety Review for Phase 3 NEAT Trial in Ataxia-Telangiectasia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-11 05:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Quince <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Safety Review for Phase 3 NEAT Trial in Ataxia-Telangiectasia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Quince Therapeutics Inc. announced a positive outcome from a pre-planned safety analysis conducted by an independent data and safety monitoring board (iDSMB) for its ongoing pivotal Phase 3 NEAT clinical trial. The study is evaluating encapsulated dexamethasone sodium phosphate (eDSP) in patients with Ataxia-Telangiectasia (A-T). The iDSMB identified no safety concerns and recommended that the trial continue without modifications. The Phase 3 NEAT study is a randomized, double-blind, placebo-controlled trial assessing the neurological effects of eDSP. Topline results from the study are expected to be reported in the first quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251021956399) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QNCX","symbol_name":"Quince Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLb8JL0x:1","article_id":"2582800808","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582800808","pubTimestamp":1762808772,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Quince Therapeutics Inc. announced a positive outcome from a pre-planned safety analysis conducted by an independent data and safety monitoring board  for its ongoing pivotal Phase 3 NEAT clinical trial. The study is evaluating encapsulated dexamethasone sodium phosphate  in patients with Ataxia-Telangiectasia (A-T). The iDSMB identified no safety concerns and recommended that the trial continue without modifications. The Phase 3 NEAT study is a randomized, double-blind, placebo-controlled trial assessing the neurological effects of eDSP. Topline results from the study are expected to be reported in the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"QNCX":"Quince Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Quince Therapeutics报告共济失调-毛细血管扩张症3期NEAT试验的积极安全性审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QNCX":0.9},"content_text":"Quince Therapeutics Reports Positive Safety Review for Phase 3 NEAT Trial in Ataxia-Telangiectasia\n    \n\n        Quince Therapeutics Inc. announced a positive outcome from a pre-planned safety analysis conducted by an independent data and safety monitoring board (iDSMB) for its ongoing pivotal Phase 3 NEAT clinical trial. The study is evaluating encapsulated dexamethasone sodium phosphate (eDSP) in patients with Ataxia-Telangiectasia (A-T). The iDSMB identified no safety concerns and recommended that the trial continue without modifications. The Phase 3 NEAT study is a randomized, double-blind, placebo-controlled trial assessing the neurological effects of eDSP. Topline results from the study are expected to be reported in the first quarter of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251021956399) on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582800808","isCrawlerRequest":true}